Review



hrsv  (Sino Biological)


Bioz Verified Symbol Sino Biological is a verified supplier
Bioz Manufacturer Symbol Sino Biological manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    Sino Biological hrsv
    Hrsv, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 3 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/v08b+b/Human+respiratory+syncytial+virus+(RSV)+(B%2C+strain+18537)+Fusion+glycoprotein+F0+RSV-F+Protein/pm42802006-29-0-9
    Average 94 stars, based on 3 article reviews
    hrsv - by Bioz Stars, 2026-10
    94/100 stars

    Images

    Related Articles

    Recombinant:

    Article Title: Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses
    Article Snippet: 229E-CoV spike , Sino Biological , Cat. # 40605-V08B-B.

    Article Title: HKU1 immune imprinting is associated with post-COVID symptoms after SARS-CoV-2 infection
    Article Snippet: Biotinylated HKU1 spike , Sino Biological , Cat 40606-V08B-B.

    Article Title: Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses
    Article Snippet: HCoV-NL63 spike , Sino Biological , Cat. # 40604-V08B-B.

    Article Title: HKU1 immune imprinting is associated with post-COVID symptoms after SARS-CoV-2 infection
    Article Snippet: Biotinylated NL63 spike , Sino Biological , Cat 40604-V08B-B.

    Article Title: Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses
    Article Snippet: HCoV-229E spike , Sino Biological , Cat. # 40605-V08B-B.

    Article Title: Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses
    Article Snippet: NL63-CoV spike , Sino Biological , Cat. # 40604-V08B-B.

    Transfection:

    Article Title: Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses
    Article Snippet: 229E-CoV spike , Sino Biological , Cat. # 40605-V08B-B.

    Article Title: HKU1 immune imprinting is associated with post-COVID symptoms after SARS-CoV-2 infection
    Article Snippet: Biotinylated HKU1 spike , Sino Biological , Cat 40606-V08B-B.

    Article Title: Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses
    Article Snippet: HCoV-NL63 spike , Sino Biological , Cat. # 40604-V08B-B.

    Article Title: HKU1 immune imprinting is associated with post-COVID symptoms after SARS-CoV-2 infection
    Article Snippet: Biotinylated NL63 spike , Sino Biological , Cat 40604-V08B-B.

    Article Title: Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses
    Article Snippet: HCoV-229E spike , Sino Biological , Cat. # 40605-V08B-B.

    Article Title: Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses
    Article Snippet: NL63-CoV spike , Sino Biological , Cat. # 40604-V08B-B.

    Lysis:

    Article Title: Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses
    Article Snippet: 229E-CoV spike , Sino Biological , Cat. # 40605-V08B-B.

    Article Title: HKU1 immune imprinting is associated with post-COVID symptoms after SARS-CoV-2 infection
    Article Snippet: Biotinylated HKU1 spike , Sino Biological , Cat 40606-V08B-B.

    Article Title: Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses
    Article Snippet: HCoV-NL63 spike , Sino Biological , Cat. # 40604-V08B-B.

    Article Title: HKU1 immune imprinting is associated with post-COVID symptoms after SARS-CoV-2 infection
    Article Snippet: Biotinylated NL63 spike , Sino Biological , Cat 40604-V08B-B.

    Article Title: Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses
    Article Snippet: HCoV-229E spike , Sino Biological , Cat. # 40605-V08B-B.

    Article Title: Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses
    Article Snippet: NL63-CoV spike , Sino Biological , Cat. # 40604-V08B-B.

    Cell Culture:

    Article Title: Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses
    Article Snippet: 229E-CoV spike , Sino Biological , Cat. # 40605-V08B-B.

    Article Title: HKU1 immune imprinting is associated with post-COVID symptoms after SARS-CoV-2 infection
    Article Snippet: Biotinylated HKU1 spike , Sino Biological , Cat 40606-V08B-B.

    Article Title: Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses
    Article Snippet: HCoV-NL63 spike , Sino Biological , Cat. # 40604-V08B-B.

    Article Title: HKU1 immune imprinting is associated with post-COVID symptoms after SARS-CoV-2 infection
    Article Snippet: Biotinylated NL63 spike , Sino Biological , Cat 40604-V08B-B.

    Article Title: Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses
    Article Snippet: HCoV-229E spike , Sino Biological , Cat. # 40605-V08B-B.

    Article Title: Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses
    Article Snippet: NL63-CoV spike , Sino Biological , Cat. # 40604-V08B-B.

    Luciferase:

    Article Title: Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses
    Article Snippet: 229E-CoV spike , Sino Biological , Cat. # 40605-V08B-B.

    Article Title: HKU1 immune imprinting is associated with post-COVID symptoms after SARS-CoV-2 infection
    Article Snippet: Biotinylated HKU1 spike , Sino Biological , Cat 40606-V08B-B.

    Article Title: Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses
    Article Snippet: HCoV-NL63 spike , Sino Biological , Cat. # 40604-V08B-B.

    Article Title: HKU1 immune imprinting is associated with post-COVID symptoms after SARS-CoV-2 infection
    Article Snippet: Biotinylated NL63 spike , Sino Biological , Cat 40604-V08B-B.

    Article Title: Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses
    Article Snippet: HCoV-229E spike , Sino Biological , Cat. # 40605-V08B-B.

    Article Title: Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses
    Article Snippet: NL63-CoV spike , Sino Biological , Cat. # 40604-V08B-B.

    Expressing:

    Article Title: Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses
    Article Snippet: 229E-CoV spike , Sino Biological , Cat. # 40605-V08B-B.

    Article Title: HKU1 immune imprinting is associated with post-COVID symptoms after SARS-CoV-2 infection
    Article Snippet: Biotinylated HKU1 spike , Sino Biological , Cat 40606-V08B-B.

    Article Title: Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses
    Article Snippet: HCoV-NL63 spike , Sino Biological , Cat. # 40604-V08B-B.

    Article Title: HKU1 immune imprinting is associated with post-COVID symptoms after SARS-CoV-2 infection
    Article Snippet: Biotinylated NL63 spike , Sino Biological , Cat 40604-V08B-B.

    Article Title: Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses
    Article Snippet: HCoV-229E spike , Sino Biological , Cat. # 40605-V08B-B.

    Article Title: Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses
    Article Snippet: NL63-CoV spike , Sino Biological , Cat. # 40604-V08B-B.

    Irradiation:

    Article Title: Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses
    Article Snippet: 229E-CoV spike , Sino Biological , Cat. # 40605-V08B-B.

    Article Title: HKU1 immune imprinting is associated with post-COVID symptoms after SARS-CoV-2 infection
    Article Snippet: Biotinylated HKU1 spike , Sino Biological , Cat 40606-V08B-B.

    Article Title: Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses
    Article Snippet: HCoV-NL63 spike , Sino Biological , Cat. # 40604-V08B-B.

    Article Title: HKU1 immune imprinting is associated with post-COVID symptoms after SARS-CoV-2 infection
    Article Snippet: Biotinylated NL63 spike , Sino Biological , Cat 40604-V08B-B.

    Article Title: Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses
    Article Snippet: HCoV-229E spike , Sino Biological , Cat. # 40605-V08B-B.

    Article Title: Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses
    Article Snippet: NL63-CoV spike , Sino Biological , Cat. # 40604-V08B-B.

    Amplification:

    Article Title: Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses
    Article Snippet: 229E-CoV spike , Sino Biological , Cat. # 40605-V08B-B.

    Article Title: HKU1 immune imprinting is associated with post-COVID symptoms after SARS-CoV-2 infection
    Article Snippet: Biotinylated HKU1 spike , Sino Biological , Cat 40606-V08B-B.

    Article Title: Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses
    Article Snippet: HCoV-NL63 spike , Sino Biological , Cat. # 40604-V08B-B.

    Article Title: HKU1 immune imprinting is associated with post-COVID symptoms after SARS-CoV-2 infection
    Article Snippet: Biotinylated NL63 spike , Sino Biological , Cat 40604-V08B-B.

    Article Title: Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses
    Article Snippet: HCoV-229E spike , Sino Biological , Cat. # 40605-V08B-B.

    Article Title: Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses
    Article Snippet: NL63-CoV spike , Sino Biological , Cat. # 40604-V08B-B.

    Plasmid Preparation:

    Article Title: Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses
    Article Snippet: 229E-CoV spike , Sino Biological , Cat. # 40605-V08B-B.

    Article Title: HKU1 immune imprinting is associated with post-COVID symptoms after SARS-CoV-2 infection
    Article Snippet: Biotinylated HKU1 spike , Sino Biological , Cat 40606-V08B-B.

    Article Title: Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses
    Article Snippet: HCoV-NL63 spike , Sino Biological , Cat. # 40604-V08B-B.

    Article Title: HKU1 immune imprinting is associated with post-COVID symptoms after SARS-CoV-2 infection
    Article Snippet: Biotinylated NL63 spike , Sino Biological , Cat 40604-V08B-B.

    Article Title: Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses
    Article Snippet: HCoV-229E spike , Sino Biological , Cat. # 40605-V08B-B.

    Article Title: Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses
    Article Snippet: NL63-CoV spike , Sino Biological , Cat. # 40604-V08B-B.

    Software:

    Article Title: Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses
    Article Snippet: 229E-CoV spike , Sino Biological , Cat. # 40605-V08B-B.

    Article Title: HKU1 immune imprinting is associated with post-COVID symptoms after SARS-CoV-2 infection
    Article Snippet: Biotinylated HKU1 spike , Sino Biological , Cat 40606-V08B-B.

    Article Title: Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses
    Article Snippet: HCoV-NL63 spike , Sino Biological , Cat. # 40604-V08B-B.

    Article Title: HKU1 immune imprinting is associated with post-COVID symptoms after SARS-CoV-2 infection
    Article Snippet: Biotinylated NL63 spike , Sino Biological , Cat 40604-V08B-B.

    Article Title: Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses
    Article Snippet: HCoV-229E spike , Sino Biological , Cat. # 40605-V08B-B.

    Article Title: Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses
    Article Snippet: NL63-CoV spike , Sino Biological , Cat. # 40604-V08B-B.

    Fluorescence:

    Article Title: Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses
    Article Snippet: 229E-CoV spike , Sino Biological , Cat. # 40605-V08B-B.

    Article Title: HKU1 immune imprinting is associated with post-COVID symptoms after SARS-CoV-2 infection
    Article Snippet: Biotinylated HKU1 spike , Sino Biological , Cat 40606-V08B-B.

    Article Title: Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses
    Article Snippet: HCoV-NL63 spike , Sino Biological , Cat. # 40604-V08B-B.

    Article Title: HKU1 immune imprinting is associated with post-COVID symptoms after SARS-CoV-2 infection
    Article Snippet: Biotinylated NL63 spike , Sino Biological , Cat 40604-V08B-B.

    Article Title: Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses
    Article Snippet: HCoV-229E spike , Sino Biological , Cat. # 40605-V08B-B.

    Article Title: Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses
    Article Snippet: NL63-CoV spike , Sino Biological , Cat. # 40604-V08B-B.

    Microscopy:

    Article Title: Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses
    Article Snippet: 229E-CoV spike , Sino Biological , Cat. # 40605-V08B-B.

    Article Title: HKU1 immune imprinting is associated with post-COVID symptoms after SARS-CoV-2 infection
    Article Snippet: Biotinylated HKU1 spike , Sino Biological , Cat 40606-V08B-B.

    Article Title: Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses
    Article Snippet: HCoV-NL63 spike , Sino Biological , Cat. # 40604-V08B-B.

    Article Title: HKU1 immune imprinting is associated with post-COVID symptoms after SARS-CoV-2 infection
    Article Snippet: Biotinylated NL63 spike , Sino Biological , Cat 40604-V08B-B.

    Article Title: Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses
    Article Snippet: HCoV-229E spike , Sino Biological , Cat. # 40605-V08B-B.

    Article Title: Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses
    Article Snippet: NL63-CoV spike , Sino Biological , Cat. # 40604-V08B-B.

    Imaging:

    Article Title: Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses
    Article Snippet: 229E-CoV spike , Sino Biological , Cat. # 40605-V08B-B.

    Article Title: HKU1 immune imprinting is associated with post-COVID symptoms after SARS-CoV-2 infection
    Article Snippet: Biotinylated HKU1 spike , Sino Biological , Cat 40606-V08B-B.

    Article Title: Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses
    Article Snippet: HCoV-NL63 spike , Sino Biological , Cat. # 40604-V08B-B.

    Article Title: HKU1 immune imprinting is associated with post-COVID symptoms after SARS-CoV-2 infection
    Article Snippet: Biotinylated NL63 spike , Sino Biological , Cat 40604-V08B-B.

    Article Title: Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses
    Article Snippet: HCoV-229E spike , Sino Biological , Cat. # 40605-V08B-B.

    Article Title: Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses
    Article Snippet: NL63-CoV spike , Sino Biological , Cat. # 40604-V08B-B.



    Similar Products

    hrsv  (Sino Biological)
    94
    Sino Biological hrsv
    Hrsv, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/v08b+b/Human+respiratory+syncytial+virus+(RSV)+(B%2C+strain+18537)+Fusion+glycoprotein+F0+RSV-F+Protein/pm42802006-29-0-9
    Average 94 stars, based on 1 article reviews
    hrsv - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    40604-v08b-b  (Sino Biological)
    94
    Sino Biological 40604-v08b-b
    40604 V08b B, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/v08b+b/Human+coronavirus+(HCoV-NL63)+Spike+S1%2BS2+Protein+(ECD%2C+His+Tag)%2C+Biotinylated/pmc12999348-32-0-4
    Average 94 stars, based on 1 article reviews
    40604-v08b-b - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    human coronavirus (hcov-nl63) spike s1+s2 protein (ecd, his tag), biotinylated  (Sino Biological)
    94
    Sino Biological human coronavirus (hcov-nl63) spike s1+s2 protein (ecd, his tag), biotinylated
    Human Coronavirus (Hcov Nl63) Spike S1+S2 Protein (Ecd, His Tag), Biotinylated, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/v08b+b/Human+coronavirus+(HCoV-NL63)+Spike+S1%2BS2+Protein+(ECD%2C+His+Tag)%2C+Biotinylated/custom%4040604-v08b-b%4010%2E1016%2Fj%2Eisci%2E2026%2E115175
    Average 94 stars, based on 1 article reviews
    human coronavirus (hcov-nl63) spike s1+s2 protein (ecd, his tag), biotinylated - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    v08b b  (Sino Biological)
    94
    Sino Biological v08b b
    V08b B, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/v08b+b/Human+coronavirus+(HCoV-NL63)+Spike+S1%2BS2+Protein+(ECD%2C+His+Tag)%2C+Biotinylated/pmc12999348-32-8-4
    Average 94 stars, based on 1 article reviews
    v08b b - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    biotinylated hku1 spike proteins  (Sino Biological)
    94
    Sino Biological biotinylated hku1 spike proteins
    SARS-CoV-2 vaccination boosts pre-existing antibody reactivity to human coronaviruses (HCoVs) (A) Timeline of vaccine administration and peripheral blood sampling in the first (healthcare workers) cohort. (B) IgG responses to the spike protein of SARS-CoV-2 and HCoVs (OC43, <t>HKU1,</t> NL63, and 229E) expressed as arbitrary units per milliliter (AU/mL), shown as box (median, with lower/higher quartiles)-and-whiskers (upper whisker: Q3+1.5xIQR, lower whisker: Q1-1.5xIQR) plots, with all data points. (C) Relative IgG avidity profiles against SARS-CoV-2 and HCoV spike, across time points, with LOESS-smoothed trend lines, showing all data points and 95% confidence intervals (gray shade). (D) Corresponding avidity ranges for SARS-CoV-2 and HCoV spike antigen, shown as box-and-whisker plots (similarly defined as in [B]), with all data points. Paired comparisons were conducted between baseline and 14 days after the first vaccine dose, and between 28 days after the first dose and 14 days after the second dose, using a mixed-effects model (∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001). Sample sizes: baseline ( n = 48), 14 days post-first dose ( n = 46), 28 days post-first dose ( n = 35), 14 days post-second dose ( n = 15), and 28 days post-second dose ( n = 11).
    Biotinylated Hku1 Spike Proteins, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/v08b+b/Human+coronavirus+HKU1+(isolate+N5)+(HCoV-HKU1)+Spike+S1%2BS2+Protein+(ECD%2C+His+Tag)%2C+Biotinylated/pmc12999348-253-4-11
    Average 94 stars, based on 1 article reviews
    biotinylated hku1 spike proteins - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    nl63  (Sino Biological)
    94
    Sino Biological nl63
    SARS-CoV-2 vaccination boosts pre-existing antibody reactivity to human coronaviruses (HCoVs) (A) Timeline of vaccine administration and peripheral blood sampling in the first (healthcare workers) cohort. (B) IgG responses to the spike protein of SARS-CoV-2 and HCoVs (OC43, HKU1, <t>NL63,</t> and 229E) expressed as arbitrary units per milliliter (AU/mL), shown as box (median, with lower/higher quartiles)-and-whiskers (upper whisker: Q3+1.5xIQR, lower whisker: Q1-1.5xIQR) plots, with all data points. (C) Relative IgG avidity profiles against SARS-CoV-2 and HCoV spike, across time points, with LOESS-smoothed trend lines, showing all data points and 95% confidence intervals (gray shade). (D) Corresponding avidity ranges for SARS-CoV-2 and HCoV spike antigen, shown as box-and-whisker plots (similarly defined as in [B]), with all data points. Paired comparisons were conducted between baseline and 14 days after the first vaccine dose, and between 28 days after the first dose and 14 days after the second dose, using a mixed-effects model (∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001). Sample sizes: baseline ( n = 48), 14 days post-first dose ( n = 46), 28 days post-first dose ( n = 35), 14 days post-second dose ( n = 15), and 28 days post-second dose ( n = 11).
    Nl63, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/v08b+b/Human+coronavirus+(HCoV-NL63)+Spike+S1%2BS2+Protein+(ECD%2C+His+Tag)%2C+Biotinylated/pmc12999348-259-42-43
    Average 94 stars, based on 1 article reviews
    nl63 - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    40606-v08b-b  (Sino Biological)
    94
    Sino Biological 40606-v08b-b
    SARS-CoV-2 vaccination boosts pre-existing antibody reactivity to human coronaviruses (HCoVs) (A) Timeline of vaccine administration and peripheral blood sampling in the first (healthcare workers) cohort. (B) IgG responses to the spike protein of SARS-CoV-2 and HCoVs (OC43, HKU1, <t>NL63,</t> and 229E) expressed as arbitrary units per milliliter (AU/mL), shown as box (median, with lower/higher quartiles)-and-whiskers (upper whisker: Q3+1.5xIQR, lower whisker: Q1-1.5xIQR) plots, with all data points. (C) Relative IgG avidity profiles against SARS-CoV-2 and HCoV spike, across time points, with LOESS-smoothed trend lines, showing all data points and 95% confidence intervals (gray shade). (D) Corresponding avidity ranges for SARS-CoV-2 and HCoV spike antigen, shown as box-and-whisker plots (similarly defined as in [B]), with all data points. Paired comparisons were conducted between baseline and 14 days after the first vaccine dose, and between 28 days after the first dose and 14 days after the second dose, using a mixed-effects model (∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001). Sample sizes: baseline ( n = 48), 14 days post-first dose ( n = 46), 28 days post-first dose ( n = 35), 14 days post-second dose ( n = 15), and 28 days post-second dose ( n = 11).
    40606 V08b B, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/v08b+b/Human+coronavirus+HKU1+(isolate+N5)+(HCoV-HKU1)+Spike+S1%2BS2+Protein+(ECD%2C+His+Tag)%2C+Biotinylated/pmc12999348-26-0-4
    Average 94 stars, based on 1 article reviews
    40606-v08b-b - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    hku1  (Sino Biological)
    94
    Sino Biological hku1
    SARS-CoV-2 vaccination boosts pre-existing antibody reactivity to human coronaviruses (HCoVs) (A) Timeline of vaccine administration and peripheral blood sampling in the first (healthcare workers) cohort. (B) IgG responses to the spike protein of SARS-CoV-2 and HCoVs (OC43, <t>HKU1,</t> NL63, and 229E) expressed as arbitrary units per milliliter (AU/mL), shown as box (median, with lower/higher quartiles)-and-whiskers (upper whisker: Q3+1.5xIQR, lower whisker: Q1-1.5xIQR) plots, with all data points. (C) Relative IgG avidity profiles against SARS-CoV-2 and HCoV spike, across time points, with LOESS-smoothed trend lines, showing all data points and 95% confidence intervals (gray shade). (D) Corresponding avidity ranges for SARS-CoV-2 and HCoV spike antigen, shown as box-and-whisker plots (similarly defined as in [B]), with all data points. Paired comparisons were conducted between baseline and 14 days after the first vaccine dose, and between 28 days after the first dose and 14 days after the second dose, using a mixed-effects model (∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001). Sample sizes: baseline ( n = 48), 14 days post-first dose ( n = 46), 28 days post-first dose ( n = 35), 14 days post-second dose ( n = 15), and 28 days post-second dose ( n = 11).
    Hku1, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/v08b+b/Human+coronavirus+HKU1+(isolate+N5)+(HCoV-HKU1)+Spike+S1%2BS2+Protein+(ECD%2C+His+Tag)%2C+Biotinylated/pmc12999348-259-36-37
    Average 94 stars, based on 1 article reviews
    hku1 - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    SARS-CoV-2 vaccination boosts pre-existing antibody reactivity to human coronaviruses (HCoVs) (A) Timeline of vaccine administration and peripheral blood sampling in the first (healthcare workers) cohort. (B) IgG responses to the spike protein of SARS-CoV-2 and HCoVs (OC43, HKU1, NL63, and 229E) expressed as arbitrary units per milliliter (AU/mL), shown as box (median, with lower/higher quartiles)-and-whiskers (upper whisker: Q3+1.5xIQR, lower whisker: Q1-1.5xIQR) plots, with all data points. (C) Relative IgG avidity profiles against SARS-CoV-2 and HCoV spike, across time points, with LOESS-smoothed trend lines, showing all data points and 95% confidence intervals (gray shade). (D) Corresponding avidity ranges for SARS-CoV-2 and HCoV spike antigen, shown as box-and-whisker plots (similarly defined as in [B]), with all data points. Paired comparisons were conducted between baseline and 14 days after the first vaccine dose, and between 28 days after the first dose and 14 days after the second dose, using a mixed-effects model (∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001). Sample sizes: baseline ( n = 48), 14 days post-first dose ( n = 46), 28 days post-first dose ( n = 35), 14 days post-second dose ( n = 15), and 28 days post-second dose ( n = 11).

    Journal: iScience

    Article Title: HKU1 immune imprinting is associated with post-COVID symptoms after SARS-CoV-2 infection

    doi: 10.1016/j.isci.2026.115175

    Figure Lengend Snippet: SARS-CoV-2 vaccination boosts pre-existing antibody reactivity to human coronaviruses (HCoVs) (A) Timeline of vaccine administration and peripheral blood sampling in the first (healthcare workers) cohort. (B) IgG responses to the spike protein of SARS-CoV-2 and HCoVs (OC43, HKU1, NL63, and 229E) expressed as arbitrary units per milliliter (AU/mL), shown as box (median, with lower/higher quartiles)-and-whiskers (upper whisker: Q3+1.5xIQR, lower whisker: Q1-1.5xIQR) plots, with all data points. (C) Relative IgG avidity profiles against SARS-CoV-2 and HCoV spike, across time points, with LOESS-smoothed trend lines, showing all data points and 95% confidence intervals (gray shade). (D) Corresponding avidity ranges for SARS-CoV-2 and HCoV spike antigen, shown as box-and-whisker plots (similarly defined as in [B]), with all data points. Paired comparisons were conducted between baseline and 14 days after the first vaccine dose, and between 28 days after the first dose and 14 days after the second dose, using a mixed-effects model (∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001). Sample sizes: baseline ( n = 48), 14 days post-first dose ( n = 46), 28 days post-first dose ( n = 35), 14 days post-second dose ( n = 15), and 28 days post-second dose ( n = 11).

    Article Snippet: For HKU1-specific B cells, biotinylated HKU1 spike proteins were purchased from Sino Biological, Beijing, China (cat# 40606-V08B-B).

    Techniques: Sampling, Whisker Assay

    HKU1 immune imprinting predominantly targets the SARS-CoV-2 S2 domain Percentages of antigen-specific memory B cells, IgG + B cells, or plasmablasts calculated as the number of antigen-specific cells within each subset divided by total B cells, IgG + B cells, or plasmablasts, respectively, across time points (flow cytometry). Log10-transformed data are shown as box (median, with lower/higher quartiles)-and-whiskers (upper whisker: Q3+1.5xIQR, lower whisker: Q1-1.5xIQR) plots, with all data points, and LOESS-smoothed trend lines with 95% confidence intervals (gray shade). (A–C) Percentage of S1 and S2-specific cells within memory and IgG+ memory B cells, and plasmablasts. Comparisons were performed between S1 and S2 groups using a Wilcoxon signed-rank test. (D–F) Percentages of HKU1-specific B cells within total and IgG+ memory B cells, and plasmablasts. Comparisons assessed between sequential vaccine time point pairs, using mixed-effects models (only significant results are shown; ∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001). Sample sizes: baseline ( n = 20); 14 days ( n = 30) and 28 days post-first dose ( n = 19); and 14 days ( n = 22) and 28 days post-second dose ( n = 18).

    Journal: iScience

    Article Title: HKU1 immune imprinting is associated with post-COVID symptoms after SARS-CoV-2 infection

    doi: 10.1016/j.isci.2026.115175

    Figure Lengend Snippet: HKU1 immune imprinting predominantly targets the SARS-CoV-2 S2 domain Percentages of antigen-specific memory B cells, IgG + B cells, or plasmablasts calculated as the number of antigen-specific cells within each subset divided by total B cells, IgG + B cells, or plasmablasts, respectively, across time points (flow cytometry). Log10-transformed data are shown as box (median, with lower/higher quartiles)-and-whiskers (upper whisker: Q3+1.5xIQR, lower whisker: Q1-1.5xIQR) plots, with all data points, and LOESS-smoothed trend lines with 95% confidence intervals (gray shade). (A–C) Percentage of S1 and S2-specific cells within memory and IgG+ memory B cells, and plasmablasts. Comparisons were performed between S1 and S2 groups using a Wilcoxon signed-rank test. (D–F) Percentages of HKU1-specific B cells within total and IgG+ memory B cells, and plasmablasts. Comparisons assessed between sequential vaccine time point pairs, using mixed-effects models (only significant results are shown; ∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001). Sample sizes: baseline ( n = 20); 14 days ( n = 30) and 28 days post-first dose ( n = 19); and 14 days ( n = 22) and 28 days post-second dose ( n = 18).

    Article Snippet: For HKU1-specific B cells, biotinylated HKU1 spike proteins were purchased from Sino Biological, Beijing, China (cat# 40606-V08B-B).

    Techniques: Flow Cytometry, Transformation Assay, Whisker Assay

    Recalled HKU1 spike antibody responses display enhanced ADCP function (A) Antibody-dependent cellular phagocytosis (ADCP) responses against HCoV spike and SARS-CoV-2 S1- and S2-domains across vaccine doses and time points. ADCP scores were compared between baseline and 14 days post-first dose, and between 28 days post-first dose and 14 days post-second dose, using a mixed-effects model. Data are shown as box (median, with lower/higher quartiles)-and-whiskers (upper whisker: Q3+1.5xIQR, lower whisker: Q1-1.5xIQR) plots, with all data points. (B) Spearman correlations between HKU1 and NL63 spike, and SARS-CoV-2 S1- and S2-domain-specific ADCP responses, adjusted for multiple comparisons with the Benjamini-Hochberg method. Spearman correlations are shown as a heatmap for each time point. (only significant results are shown; ∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001). Sample sizes: baseline ( n = 48), 14 days post-first dose ( n = 46), 28 days post-first dose ( n = 35), 14 days post-second dose ( n = 15), and 28 days post-second dose ( n = 11).

    Journal: iScience

    Article Title: HKU1 immune imprinting is associated with post-COVID symptoms after SARS-CoV-2 infection

    doi: 10.1016/j.isci.2026.115175

    Figure Lengend Snippet: Recalled HKU1 spike antibody responses display enhanced ADCP function (A) Antibody-dependent cellular phagocytosis (ADCP) responses against HCoV spike and SARS-CoV-2 S1- and S2-domains across vaccine doses and time points. ADCP scores were compared between baseline and 14 days post-first dose, and between 28 days post-first dose and 14 days post-second dose, using a mixed-effects model. Data are shown as box (median, with lower/higher quartiles)-and-whiskers (upper whisker: Q3+1.5xIQR, lower whisker: Q1-1.5xIQR) plots, with all data points. (B) Spearman correlations between HKU1 and NL63 spike, and SARS-CoV-2 S1- and S2-domain-specific ADCP responses, adjusted for multiple comparisons with the Benjamini-Hochberg method. Spearman correlations are shown as a heatmap for each time point. (only significant results are shown; ∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001). Sample sizes: baseline ( n = 48), 14 days post-first dose ( n = 46), 28 days post-first dose ( n = 35), 14 days post-second dose ( n = 15), and 28 days post-second dose ( n = 11).

    Article Snippet: For HKU1-specific B cells, biotinylated HKU1 spike proteins were purchased from Sino Biological, Beijing, China (cat# 40606-V08B-B).

    Techniques: Whisker Assay

    HKU1 antibody reactivity was protective against SARS-CoV-2 infection but increased the risk of post-COVID symptoms in vaccinated, infection-naive individuals (A) Comparison of HCoV spike IgG levels (HKU1, OC43, NL63, and 229E; log-transformed data) at baseline, between individuals infected and those who were not at the one-year follow-up. Comparisons were performed using a Wilcoxon rank-sum test ( n = 700, infected = 509, uninfected = 191). (B) Effects of HCoV spike IgG levels, time interval between the first and second vaccine dose (days), use of mRNA vaccines only, sex, and age at baseline, on the risk of SARS-CoV-2 infection at the one-year follow-up. (C) Comparison of HCoV spike IgG levels at baseline, between individuals who developed post-COVID symptoms versus those who did not, by the one-year follow-up visit. Comparisons were performed using a Wilcoxon rank-sum test ( n = 509, post-COVID symptoms = 165, no post-COVID symptoms = 335; missing data = 9). (D) Effects of HCoV spike IgG levels, time interval between the first and second dose (days), use of mRNA vaccines only, sex, and age at baseline, on the risk of post-COVID symptoms at the one-year follow-up. (B and D) Show adjusted odds ratios with 95% confidence intervals on a logarithmic scale (in blue) where the dashed horizontal line indicates no effect (OR = 1), with corresponding p -values (in red). (E–G) Antibody-dependent complement deposition (ADCD) between individuals with the highest (78 th centile, n = 88) and lowest (22 nd centile, n = 88) HKU1 spike (E), SARS-CoV-2 S1 (F) and S2 (G) IgG levels. Comparisons were performed using a Wilcoxon rank-sum test. For (A, C, E–G) data are shown as box (median, with lower/higher quartiles)-and-whiskers (upper whisker: Q3+1.5xIQR, lower whisker: Q1-1.5xIQR) plots, with all data points. For (B, D): Odds Ratios (OR) with 95% confidence intervals (blue line) and p value (in red), on a log scale. (∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001).

    Journal: iScience

    Article Title: HKU1 immune imprinting is associated with post-COVID symptoms after SARS-CoV-2 infection

    doi: 10.1016/j.isci.2026.115175

    Figure Lengend Snippet: HKU1 antibody reactivity was protective against SARS-CoV-2 infection but increased the risk of post-COVID symptoms in vaccinated, infection-naive individuals (A) Comparison of HCoV spike IgG levels (HKU1, OC43, NL63, and 229E; log-transformed data) at baseline, between individuals infected and those who were not at the one-year follow-up. Comparisons were performed using a Wilcoxon rank-sum test ( n = 700, infected = 509, uninfected = 191). (B) Effects of HCoV spike IgG levels, time interval between the first and second vaccine dose (days), use of mRNA vaccines only, sex, and age at baseline, on the risk of SARS-CoV-2 infection at the one-year follow-up. (C) Comparison of HCoV spike IgG levels at baseline, between individuals who developed post-COVID symptoms versus those who did not, by the one-year follow-up visit. Comparisons were performed using a Wilcoxon rank-sum test ( n = 509, post-COVID symptoms = 165, no post-COVID symptoms = 335; missing data = 9). (D) Effects of HCoV spike IgG levels, time interval between the first and second dose (days), use of mRNA vaccines only, sex, and age at baseline, on the risk of post-COVID symptoms at the one-year follow-up. (B and D) Show adjusted odds ratios with 95% confidence intervals on a logarithmic scale (in blue) where the dashed horizontal line indicates no effect (OR = 1), with corresponding p -values (in red). (E–G) Antibody-dependent complement deposition (ADCD) between individuals with the highest (78 th centile, n = 88) and lowest (22 nd centile, n = 88) HKU1 spike (E), SARS-CoV-2 S1 (F) and S2 (G) IgG levels. Comparisons were performed using a Wilcoxon rank-sum test. For (A, C, E–G) data are shown as box (median, with lower/higher quartiles)-and-whiskers (upper whisker: Q3+1.5xIQR, lower whisker: Q1-1.5xIQR) plots, with all data points. For (B, D): Odds Ratios (OR) with 95% confidence intervals (blue line) and p value (in red), on a log scale. (∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001).

    Article Snippet: For HKU1-specific B cells, biotinylated HKU1 spike proteins were purchased from Sino Biological, Beijing, China (cat# 40606-V08B-B).

    Techniques: Infection, Comparison, Transformation Assay, Vaccines, Whisker Assay

    SARS-CoV-2 vaccination boosts pre-existing antibody reactivity to human coronaviruses (HCoVs) (A) Timeline of vaccine administration and peripheral blood sampling in the first (healthcare workers) cohort. (B) IgG responses to the spike protein of SARS-CoV-2 and HCoVs (OC43, HKU1, NL63, and 229E) expressed as arbitrary units per milliliter (AU/mL), shown as box (median, with lower/higher quartiles)-and-whiskers (upper whisker: Q3+1.5xIQR, lower whisker: Q1-1.5xIQR) plots, with all data points. (C) Relative IgG avidity profiles against SARS-CoV-2 and HCoV spike, across time points, with LOESS-smoothed trend lines, showing all data points and 95% confidence intervals (gray shade). (D) Corresponding avidity ranges for SARS-CoV-2 and HCoV spike antigen, shown as box-and-whisker plots (similarly defined as in [B]), with all data points. Paired comparisons were conducted between baseline and 14 days after the first vaccine dose, and between 28 days after the first dose and 14 days after the second dose, using a mixed-effects model (∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001). Sample sizes: baseline ( n = 48), 14 days post-first dose ( n = 46), 28 days post-first dose ( n = 35), 14 days post-second dose ( n = 15), and 28 days post-second dose ( n = 11).

    Journal: iScience

    Article Title: HKU1 immune imprinting is associated with post-COVID symptoms after SARS-CoV-2 infection

    doi: 10.1016/j.isci.2026.115175

    Figure Lengend Snippet: SARS-CoV-2 vaccination boosts pre-existing antibody reactivity to human coronaviruses (HCoVs) (A) Timeline of vaccine administration and peripheral blood sampling in the first (healthcare workers) cohort. (B) IgG responses to the spike protein of SARS-CoV-2 and HCoVs (OC43, HKU1, NL63, and 229E) expressed as arbitrary units per milliliter (AU/mL), shown as box (median, with lower/higher quartiles)-and-whiskers (upper whisker: Q3+1.5xIQR, lower whisker: Q1-1.5xIQR) plots, with all data points. (C) Relative IgG avidity profiles against SARS-CoV-2 and HCoV spike, across time points, with LOESS-smoothed trend lines, showing all data points and 95% confidence intervals (gray shade). (D) Corresponding avidity ranges for SARS-CoV-2 and HCoV spike antigen, shown as box-and-whisker plots (similarly defined as in [B]), with all data points. Paired comparisons were conducted between baseline and 14 days after the first vaccine dose, and between 28 days after the first dose and 14 days after the second dose, using a mixed-effects model (∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001). Sample sizes: baseline ( n = 48), 14 days post-first dose ( n = 46), 28 days post-first dose ( n = 35), 14 days post-second dose ( n = 15), and 28 days post-second dose ( n = 11).

    Article Snippet: Ten μL of yellow-green fluorescent NeutrAvidin-labeled microspheres (Thermo Fisher Scientific, Waltham, MA, USA; cat# F8776) were washed with PBS containing 0.1% BSA, resuspended in 10 μL of biotinylated SARS-CoV-2 S1, S2 (ACROBiosystems, cat# S1N-C82E8 and S2N-C52E8), HKU1 (Sino Biological, cat# 40606-V08B-B), and NL63 (Sino Biological, cat# 40604-V08B-B) spike proteins (0.1 μg/μL), and incubated at 36 °C for 2 h. Microspheres were washed twice, resuspended in 1 mL PBS, and aliquoted (10 μL) into a 96-well plate.

    Techniques: Sampling, Whisker Assay

    Recalled HKU1 spike antibody responses display enhanced ADCP function (A) Antibody-dependent cellular phagocytosis (ADCP) responses against HCoV spike and SARS-CoV-2 S1- and S2-domains across vaccine doses and time points. ADCP scores were compared between baseline and 14 days post-first dose, and between 28 days post-first dose and 14 days post-second dose, using a mixed-effects model. Data are shown as box (median, with lower/higher quartiles)-and-whiskers (upper whisker: Q3+1.5xIQR, lower whisker: Q1-1.5xIQR) plots, with all data points. (B) Spearman correlations between HKU1 and NL63 spike, and SARS-CoV-2 S1- and S2-domain-specific ADCP responses, adjusted for multiple comparisons with the Benjamini-Hochberg method. Spearman correlations are shown as a heatmap for each time point. (only significant results are shown; ∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001). Sample sizes: baseline ( n = 48), 14 days post-first dose ( n = 46), 28 days post-first dose ( n = 35), 14 days post-second dose ( n = 15), and 28 days post-second dose ( n = 11).

    Journal: iScience

    Article Title: HKU1 immune imprinting is associated with post-COVID symptoms after SARS-CoV-2 infection

    doi: 10.1016/j.isci.2026.115175

    Figure Lengend Snippet: Recalled HKU1 spike antibody responses display enhanced ADCP function (A) Antibody-dependent cellular phagocytosis (ADCP) responses against HCoV spike and SARS-CoV-2 S1- and S2-domains across vaccine doses and time points. ADCP scores were compared between baseline and 14 days post-first dose, and between 28 days post-first dose and 14 days post-second dose, using a mixed-effects model. Data are shown as box (median, with lower/higher quartiles)-and-whiskers (upper whisker: Q3+1.5xIQR, lower whisker: Q1-1.5xIQR) plots, with all data points. (B) Spearman correlations between HKU1 and NL63 spike, and SARS-CoV-2 S1- and S2-domain-specific ADCP responses, adjusted for multiple comparisons with the Benjamini-Hochberg method. Spearman correlations are shown as a heatmap for each time point. (only significant results are shown; ∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001). Sample sizes: baseline ( n = 48), 14 days post-first dose ( n = 46), 28 days post-first dose ( n = 35), 14 days post-second dose ( n = 15), and 28 days post-second dose ( n = 11).

    Article Snippet: Ten μL of yellow-green fluorescent NeutrAvidin-labeled microspheres (Thermo Fisher Scientific, Waltham, MA, USA; cat# F8776) were washed with PBS containing 0.1% BSA, resuspended in 10 μL of biotinylated SARS-CoV-2 S1, S2 (ACROBiosystems, cat# S1N-C82E8 and S2N-C52E8), HKU1 (Sino Biological, cat# 40606-V08B-B), and NL63 (Sino Biological, cat# 40604-V08B-B) spike proteins (0.1 μg/μL), and incubated at 36 °C for 2 h. Microspheres were washed twice, resuspended in 1 mL PBS, and aliquoted (10 μL) into a 96-well plate.

    Techniques: Whisker Assay

    HKU1 antibody reactivity was protective against SARS-CoV-2 infection but increased the risk of post-COVID symptoms in vaccinated, infection-naive individuals (A) Comparison of HCoV spike IgG levels (HKU1, OC43, NL63, and 229E; log-transformed data) at baseline, between individuals infected and those who were not at the one-year follow-up. Comparisons were performed using a Wilcoxon rank-sum test ( n = 700, infected = 509, uninfected = 191). (B) Effects of HCoV spike IgG levels, time interval between the first and second vaccine dose (days), use of mRNA vaccines only, sex, and age at baseline, on the risk of SARS-CoV-2 infection at the one-year follow-up. (C) Comparison of HCoV spike IgG levels at baseline, between individuals who developed post-COVID symptoms versus those who did not, by the one-year follow-up visit. Comparisons were performed using a Wilcoxon rank-sum test ( n = 509, post-COVID symptoms = 165, no post-COVID symptoms = 335; missing data = 9). (D) Effects of HCoV spike IgG levels, time interval between the first and second dose (days), use of mRNA vaccines only, sex, and age at baseline, on the risk of post-COVID symptoms at the one-year follow-up. (B and D) Show adjusted odds ratios with 95% confidence intervals on a logarithmic scale (in blue) where the dashed horizontal line indicates no effect (OR = 1), with corresponding p -values (in red). (E–G) Antibody-dependent complement deposition (ADCD) between individuals with the highest (78 th centile, n = 88) and lowest (22 nd centile, n = 88) HKU1 spike (E), SARS-CoV-2 S1 (F) and S2 (G) IgG levels. Comparisons were performed using a Wilcoxon rank-sum test. For (A, C, E–G) data are shown as box (median, with lower/higher quartiles)-and-whiskers (upper whisker: Q3+1.5xIQR, lower whisker: Q1-1.5xIQR) plots, with all data points. For (B, D): Odds Ratios (OR) with 95% confidence intervals (blue line) and p value (in red), on a log scale. (∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001).

    Journal: iScience

    Article Title: HKU1 immune imprinting is associated with post-COVID symptoms after SARS-CoV-2 infection

    doi: 10.1016/j.isci.2026.115175

    Figure Lengend Snippet: HKU1 antibody reactivity was protective against SARS-CoV-2 infection but increased the risk of post-COVID symptoms in vaccinated, infection-naive individuals (A) Comparison of HCoV spike IgG levels (HKU1, OC43, NL63, and 229E; log-transformed data) at baseline, between individuals infected and those who were not at the one-year follow-up. Comparisons were performed using a Wilcoxon rank-sum test ( n = 700, infected = 509, uninfected = 191). (B) Effects of HCoV spike IgG levels, time interval between the first and second vaccine dose (days), use of mRNA vaccines only, sex, and age at baseline, on the risk of SARS-CoV-2 infection at the one-year follow-up. (C) Comparison of HCoV spike IgG levels at baseline, between individuals who developed post-COVID symptoms versus those who did not, by the one-year follow-up visit. Comparisons were performed using a Wilcoxon rank-sum test ( n = 509, post-COVID symptoms = 165, no post-COVID symptoms = 335; missing data = 9). (D) Effects of HCoV spike IgG levels, time interval between the first and second dose (days), use of mRNA vaccines only, sex, and age at baseline, on the risk of post-COVID symptoms at the one-year follow-up. (B and D) Show adjusted odds ratios with 95% confidence intervals on a logarithmic scale (in blue) where the dashed horizontal line indicates no effect (OR = 1), with corresponding p -values (in red). (E–G) Antibody-dependent complement deposition (ADCD) between individuals with the highest (78 th centile, n = 88) and lowest (22 nd centile, n = 88) HKU1 spike (E), SARS-CoV-2 S1 (F) and S2 (G) IgG levels. Comparisons were performed using a Wilcoxon rank-sum test. For (A, C, E–G) data are shown as box (median, with lower/higher quartiles)-and-whiskers (upper whisker: Q3+1.5xIQR, lower whisker: Q1-1.5xIQR) plots, with all data points. For (B, D): Odds Ratios (OR) with 95% confidence intervals (blue line) and p value (in red), on a log scale. (∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001).

    Article Snippet: Ten μL of yellow-green fluorescent NeutrAvidin-labeled microspheres (Thermo Fisher Scientific, Waltham, MA, USA; cat# F8776) were washed with PBS containing 0.1% BSA, resuspended in 10 μL of biotinylated SARS-CoV-2 S1, S2 (ACROBiosystems, cat# S1N-C82E8 and S2N-C52E8), HKU1 (Sino Biological, cat# 40606-V08B-B), and NL63 (Sino Biological, cat# 40604-V08B-B) spike proteins (0.1 μg/μL), and incubated at 36 °C for 2 h. Microspheres were washed twice, resuspended in 1 mL PBS, and aliquoted (10 μL) into a 96-well plate.

    Techniques: Infection, Comparison, Transformation Assay, Vaccines, Whisker Assay

    SARS-CoV-2 vaccination boosts pre-existing antibody reactivity to human coronaviruses (HCoVs) (A) Timeline of vaccine administration and peripheral blood sampling in the first (healthcare workers) cohort. (B) IgG responses to the spike protein of SARS-CoV-2 and HCoVs (OC43, HKU1, NL63, and 229E) expressed as arbitrary units per milliliter (AU/mL), shown as box (median, with lower/higher quartiles)-and-whiskers (upper whisker: Q3+1.5xIQR, lower whisker: Q1-1.5xIQR) plots, with all data points. (C) Relative IgG avidity profiles against SARS-CoV-2 and HCoV spike, across time points, with LOESS-smoothed trend lines, showing all data points and 95% confidence intervals (gray shade). (D) Corresponding avidity ranges for SARS-CoV-2 and HCoV spike antigen, shown as box-and-whisker plots (similarly defined as in [B]), with all data points. Paired comparisons were conducted between baseline and 14 days after the first vaccine dose, and between 28 days after the first dose and 14 days after the second dose, using a mixed-effects model (∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001). Sample sizes: baseline ( n = 48), 14 days post-first dose ( n = 46), 28 days post-first dose ( n = 35), 14 days post-second dose ( n = 15), and 28 days post-second dose ( n = 11).

    Journal: iScience

    Article Title: HKU1 immune imprinting is associated with post-COVID symptoms after SARS-CoV-2 infection

    doi: 10.1016/j.isci.2026.115175

    Figure Lengend Snippet: SARS-CoV-2 vaccination boosts pre-existing antibody reactivity to human coronaviruses (HCoVs) (A) Timeline of vaccine administration and peripheral blood sampling in the first (healthcare workers) cohort. (B) IgG responses to the spike protein of SARS-CoV-2 and HCoVs (OC43, HKU1, NL63, and 229E) expressed as arbitrary units per milliliter (AU/mL), shown as box (median, with lower/higher quartiles)-and-whiskers (upper whisker: Q3+1.5xIQR, lower whisker: Q1-1.5xIQR) plots, with all data points. (C) Relative IgG avidity profiles against SARS-CoV-2 and HCoV spike, across time points, with LOESS-smoothed trend lines, showing all data points and 95% confidence intervals (gray shade). (D) Corresponding avidity ranges for SARS-CoV-2 and HCoV spike antigen, shown as box-and-whisker plots (similarly defined as in [B]), with all data points. Paired comparisons were conducted between baseline and 14 days after the first vaccine dose, and between 28 days after the first dose and 14 days after the second dose, using a mixed-effects model (∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001). Sample sizes: baseline ( n = 48), 14 days post-first dose ( n = 46), 28 days post-first dose ( n = 35), 14 days post-second dose ( n = 15), and 28 days post-second dose ( n = 11).

    Article Snippet: Ten μL of yellow-green fluorescent NeutrAvidin-labeled microspheres (Thermo Fisher Scientific, Waltham, MA, USA; cat# F8776) were washed with PBS containing 0.1% BSA, resuspended in 10 μL of biotinylated SARS-CoV-2 S1, S2 (ACROBiosystems, cat# S1N-C82E8 and S2N-C52E8), HKU1 (Sino Biological, cat# 40606-V08B-B), and NL63 (Sino Biological, cat# 40604-V08B-B) spike proteins (0.1 μg/μL), and incubated at 36 °C for 2 h. Microspheres were washed twice, resuspended in 1 mL PBS, and aliquoted (10 μL) into a 96-well plate.

    Techniques: Sampling, Whisker Assay

    HKU1 immune imprinting predominantly targets the SARS-CoV-2 S2 domain Percentages of antigen-specific memory B cells, IgG + B cells, or plasmablasts calculated as the number of antigen-specific cells within each subset divided by total B cells, IgG + B cells, or plasmablasts, respectively, across time points (flow cytometry). Log10-transformed data are shown as box (median, with lower/higher quartiles)-and-whiskers (upper whisker: Q3+1.5xIQR, lower whisker: Q1-1.5xIQR) plots, with all data points, and LOESS-smoothed trend lines with 95% confidence intervals (gray shade). (A–C) Percentage of S1 and S2-specific cells within memory and IgG+ memory B cells, and plasmablasts. Comparisons were performed between S1 and S2 groups using a Wilcoxon signed-rank test. (D–F) Percentages of HKU1-specific B cells within total and IgG+ memory B cells, and plasmablasts. Comparisons assessed between sequential vaccine time point pairs, using mixed-effects models (only significant results are shown; ∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001). Sample sizes: baseline ( n = 20); 14 days ( n = 30) and 28 days post-first dose ( n = 19); and 14 days ( n = 22) and 28 days post-second dose ( n = 18).

    Journal: iScience

    Article Title: HKU1 immune imprinting is associated with post-COVID symptoms after SARS-CoV-2 infection

    doi: 10.1016/j.isci.2026.115175

    Figure Lengend Snippet: HKU1 immune imprinting predominantly targets the SARS-CoV-2 S2 domain Percentages of antigen-specific memory B cells, IgG + B cells, or plasmablasts calculated as the number of antigen-specific cells within each subset divided by total B cells, IgG + B cells, or plasmablasts, respectively, across time points (flow cytometry). Log10-transformed data are shown as box (median, with lower/higher quartiles)-and-whiskers (upper whisker: Q3+1.5xIQR, lower whisker: Q1-1.5xIQR) plots, with all data points, and LOESS-smoothed trend lines with 95% confidence intervals (gray shade). (A–C) Percentage of S1 and S2-specific cells within memory and IgG+ memory B cells, and plasmablasts. Comparisons were performed between S1 and S2 groups using a Wilcoxon signed-rank test. (D–F) Percentages of HKU1-specific B cells within total and IgG+ memory B cells, and plasmablasts. Comparisons assessed between sequential vaccine time point pairs, using mixed-effects models (only significant results are shown; ∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001). Sample sizes: baseline ( n = 20); 14 days ( n = 30) and 28 days post-first dose ( n = 19); and 14 days ( n = 22) and 28 days post-second dose ( n = 18).

    Article Snippet: Ten μL of yellow-green fluorescent NeutrAvidin-labeled microspheres (Thermo Fisher Scientific, Waltham, MA, USA; cat# F8776) were washed with PBS containing 0.1% BSA, resuspended in 10 μL of biotinylated SARS-CoV-2 S1, S2 (ACROBiosystems, cat# S1N-C82E8 and S2N-C52E8), HKU1 (Sino Biological, cat# 40606-V08B-B), and NL63 (Sino Biological, cat# 40604-V08B-B) spike proteins (0.1 μg/μL), and incubated at 36 °C for 2 h. Microspheres were washed twice, resuspended in 1 mL PBS, and aliquoted (10 μL) into a 96-well plate.

    Techniques: Flow Cytometry, Transformation Assay, Whisker Assay

    Recalled HKU1 spike antibody responses display enhanced ADCP function (A) Antibody-dependent cellular phagocytosis (ADCP) responses against HCoV spike and SARS-CoV-2 S1- and S2-domains across vaccine doses and time points. ADCP scores were compared between baseline and 14 days post-first dose, and between 28 days post-first dose and 14 days post-second dose, using a mixed-effects model. Data are shown as box (median, with lower/higher quartiles)-and-whiskers (upper whisker: Q3+1.5xIQR, lower whisker: Q1-1.5xIQR) plots, with all data points. (B) Spearman correlations between HKU1 and NL63 spike, and SARS-CoV-2 S1- and S2-domain-specific ADCP responses, adjusted for multiple comparisons with the Benjamini-Hochberg method. Spearman correlations are shown as a heatmap for each time point. (only significant results are shown; ∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001). Sample sizes: baseline ( n = 48), 14 days post-first dose ( n = 46), 28 days post-first dose ( n = 35), 14 days post-second dose ( n = 15), and 28 days post-second dose ( n = 11).

    Journal: iScience

    Article Title: HKU1 immune imprinting is associated with post-COVID symptoms after SARS-CoV-2 infection

    doi: 10.1016/j.isci.2026.115175

    Figure Lengend Snippet: Recalled HKU1 spike antibody responses display enhanced ADCP function (A) Antibody-dependent cellular phagocytosis (ADCP) responses against HCoV spike and SARS-CoV-2 S1- and S2-domains across vaccine doses and time points. ADCP scores were compared between baseline and 14 days post-first dose, and between 28 days post-first dose and 14 days post-second dose, using a mixed-effects model. Data are shown as box (median, with lower/higher quartiles)-and-whiskers (upper whisker: Q3+1.5xIQR, lower whisker: Q1-1.5xIQR) plots, with all data points. (B) Spearman correlations between HKU1 and NL63 spike, and SARS-CoV-2 S1- and S2-domain-specific ADCP responses, adjusted for multiple comparisons with the Benjamini-Hochberg method. Spearman correlations are shown as a heatmap for each time point. (only significant results are shown; ∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001). Sample sizes: baseline ( n = 48), 14 days post-first dose ( n = 46), 28 days post-first dose ( n = 35), 14 days post-second dose ( n = 15), and 28 days post-second dose ( n = 11).

    Article Snippet: Ten μL of yellow-green fluorescent NeutrAvidin-labeled microspheres (Thermo Fisher Scientific, Waltham, MA, USA; cat# F8776) were washed with PBS containing 0.1% BSA, resuspended in 10 μL of biotinylated SARS-CoV-2 S1, S2 (ACROBiosystems, cat# S1N-C82E8 and S2N-C52E8), HKU1 (Sino Biological, cat# 40606-V08B-B), and NL63 (Sino Biological, cat# 40604-V08B-B) spike proteins (0.1 μg/μL), and incubated at 36 °C for 2 h. Microspheres were washed twice, resuspended in 1 mL PBS, and aliquoted (10 μL) into a 96-well plate.

    Techniques: Whisker Assay

    HKU1 antibody reactivity was protective against SARS-CoV-2 infection but increased the risk of post-COVID symptoms in vaccinated, infection-naive individuals (A) Comparison of HCoV spike IgG levels (HKU1, OC43, NL63, and 229E; log-transformed data) at baseline, between individuals infected and those who were not at the one-year follow-up. Comparisons were performed using a Wilcoxon rank-sum test ( n = 700, infected = 509, uninfected = 191). (B) Effects of HCoV spike IgG levels, time interval between the first and second vaccine dose (days), use of mRNA vaccines only, sex, and age at baseline, on the risk of SARS-CoV-2 infection at the one-year follow-up. (C) Comparison of HCoV spike IgG levels at baseline, between individuals who developed post-COVID symptoms versus those who did not, by the one-year follow-up visit. Comparisons were performed using a Wilcoxon rank-sum test ( n = 509, post-COVID symptoms = 165, no post-COVID symptoms = 335; missing data = 9). (D) Effects of HCoV spike IgG levels, time interval between the first and second dose (days), use of mRNA vaccines only, sex, and age at baseline, on the risk of post-COVID symptoms at the one-year follow-up. (B and D) Show adjusted odds ratios with 95% confidence intervals on a logarithmic scale (in blue) where the dashed horizontal line indicates no effect (OR = 1), with corresponding p -values (in red). (E–G) Antibody-dependent complement deposition (ADCD) between individuals with the highest (78 th centile, n = 88) and lowest (22 nd centile, n = 88) HKU1 spike (E), SARS-CoV-2 S1 (F) and S2 (G) IgG levels. Comparisons were performed using a Wilcoxon rank-sum test. For (A, C, E–G) data are shown as box (median, with lower/higher quartiles)-and-whiskers (upper whisker: Q3+1.5xIQR, lower whisker: Q1-1.5xIQR) plots, with all data points. For (B, D): Odds Ratios (OR) with 95% confidence intervals (blue line) and p value (in red), on a log scale. (∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001).

    Journal: iScience

    Article Title: HKU1 immune imprinting is associated with post-COVID symptoms after SARS-CoV-2 infection

    doi: 10.1016/j.isci.2026.115175

    Figure Lengend Snippet: HKU1 antibody reactivity was protective against SARS-CoV-2 infection but increased the risk of post-COVID symptoms in vaccinated, infection-naive individuals (A) Comparison of HCoV spike IgG levels (HKU1, OC43, NL63, and 229E; log-transformed data) at baseline, between individuals infected and those who were not at the one-year follow-up. Comparisons were performed using a Wilcoxon rank-sum test ( n = 700, infected = 509, uninfected = 191). (B) Effects of HCoV spike IgG levels, time interval between the first and second vaccine dose (days), use of mRNA vaccines only, sex, and age at baseline, on the risk of SARS-CoV-2 infection at the one-year follow-up. (C) Comparison of HCoV spike IgG levels at baseline, between individuals who developed post-COVID symptoms versus those who did not, by the one-year follow-up visit. Comparisons were performed using a Wilcoxon rank-sum test ( n = 509, post-COVID symptoms = 165, no post-COVID symptoms = 335; missing data = 9). (D) Effects of HCoV spike IgG levels, time interval between the first and second dose (days), use of mRNA vaccines only, sex, and age at baseline, on the risk of post-COVID symptoms at the one-year follow-up. (B and D) Show adjusted odds ratios with 95% confidence intervals on a logarithmic scale (in blue) where the dashed horizontal line indicates no effect (OR = 1), with corresponding p -values (in red). (E–G) Antibody-dependent complement deposition (ADCD) between individuals with the highest (78 th centile, n = 88) and lowest (22 nd centile, n = 88) HKU1 spike (E), SARS-CoV-2 S1 (F) and S2 (G) IgG levels. Comparisons were performed using a Wilcoxon rank-sum test. For (A, C, E–G) data are shown as box (median, with lower/higher quartiles)-and-whiskers (upper whisker: Q3+1.5xIQR, lower whisker: Q1-1.5xIQR) plots, with all data points. For (B, D): Odds Ratios (OR) with 95% confidence intervals (blue line) and p value (in red), on a log scale. (∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001).

    Article Snippet: Ten μL of yellow-green fluorescent NeutrAvidin-labeled microspheres (Thermo Fisher Scientific, Waltham, MA, USA; cat# F8776) were washed with PBS containing 0.1% BSA, resuspended in 10 μL of biotinylated SARS-CoV-2 S1, S2 (ACROBiosystems, cat# S1N-C82E8 and S2N-C52E8), HKU1 (Sino Biological, cat# 40606-V08B-B), and NL63 (Sino Biological, cat# 40604-V08B-B) spike proteins (0.1 μg/μL), and incubated at 36 °C for 2 h. Microspheres were washed twice, resuspended in 1 mL PBS, and aliquoted (10 μL) into a 96-well plate.

    Techniques: Infection, Comparison, Transformation Assay, Vaccines, Whisker Assay